Janux Therapeutics GAAP EPS of -$0.39 beats by $0.13, revenue of $3.73M misses by $0.96M
Source: SeekingAlpha
2026-05-07 17:31:13 ET
More on Janux Therapeutics
- Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value
- Janux ends development of Tumor Activated T Cell Engager asset
- Janux Therapeutics GAAP EPS of -$0.51 beats by $0.16
- Seeking Alpha’s Quant Rating on Janux Therapeutics
- Historical earnings data for Janux Therapeutics
Read the full article on Seeking Alpha
For further details see:
Janux Therapeutics GAAP EPS of -$0.39 beats by $0.13, revenue of $3.73M misses by $0.96M
Janux Therapeutics Inc.
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
JANX Latest News
May 07, 2026 04:01:00 pm
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
April 27, 2026 04:01:00 pm
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 16, 2026 04:01:00 pm
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
JANX Stock Data
$789,139,228
45,531,890
1.75%
55
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
